UNAUDITED FINANCIAL RESULTS
FOR THE QUARTER ENDED 31ST DECEMber,2001
Rs in millions
Quater Ended
Nine Months Ended
Year Ended
31.03.2001
(Audited)
31.12.2001
31.12.2000
31.12.2001
31.12.2000
1. Net Sales
3662.5
2756.4
10011.8
7870.9
10475.1
2. Other Income
152.5
81.6
333.1
257.4
386.1
3. Total Expenditure
a) (Increase)/ decrease in Stock-in -trade
(320.3)
(182.9)
(366.9)
(360.5)
(375.8)
b) Consumption of Materials
1930.7
1478.4
4936.7
3968.8
5236.6
c) Staff Cost
158.6
116.9
462.0
354.5
499.0
d) Other Expenditure
1173.2
657.3
2969.8
2099.2
2961.1
4. Interest
7.8
2.9
15.0
8.2
8.3
5. Depreciation
48.5
40.0
143.5
122.5
156.3
6. Profit (+) / Loss (-) before Tax (1+2-3-4-5)
816.5
725.4
2184.8
1935.6
2375.7
7. Provision for Taxation
*190.0
190.0
*510.0
495.0
585.0
8. Net Profit (+) / Loss (-)(6-7)
626.5
535.4
1674.8
1440.6
1790.7
9. Paid-up Equity Share Capital
599.7
599.7
599.7
599.7
599.7
10. Reserves excluding Revaluation Reserves ( as per balance-sheet of previous accounting year)
-
-
-
-
6540.5
11. Earning per Share
**Not Annualised
**10.45
**8.93
**27.93
**24.02
29.86
Notes :
* Provision for tax includes deferred taxation.
The Company is exclusively in the pharmaceutical business segment.
The Company is setting up facilities for manufacture of formulations at Verna, Goa at a capital expenditure of approximately Rs.1200 million. Commercial production has commenced in a phased manner.
The above results were taken on record at the meeting of the Board of Directors held on 19th January, 2002.
